Velg data du ønsker med i utskriften
Tittel Versjon Status
Revisjonsdato Publiseringsdato
Utgiver(e) Publikasjonstype
  • Norsk tittel - Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne melanomer
  • Engelsk tittel -
  • Versjon - 9
  • Status - Publisert
  • IS-nr - 2931
  • ISBN - 978-82-8081-620-7
  • DOI -
  • Revisjonsdato - 22.05.2020
  • Neste revisjon -
  • Publikasjonsdato - 15.11.2013
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør -
  • Publikasjonstype - Nasjonale retningslinjer
  1. Saw R, Menzies A, McArthur G, Spillane J, Haydon A, Cancer Council Australia Melanoma Guidelines Working Party. What investigations should be performed when in transit and/or regional node disease (Stage III melanoma) is diagnosed? I: Clinical practice guidelines for the diagnosis and management of melanoma [nettdokument]. Sydney: Cancer Council Australia [oppdatert 25. mai 2018; lest 17. mars 2019]. Tilgjengelig fra:
  2. Bishop JN, Bataille V, Gavin A, Lens M, Marsden J, Mathews T, et al. The prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines. Clin Med 2007;7(3):283-90.
  3. Bishop JN, Harland M, Randerson-Moor J, Bishop DT. Management of familial melanoma. Lancet Oncol 2007;8(1):46-54.
  4. Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 2004;292(22):2771-6.
  5. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985;35(3):130-51.
  6. Kelly JW, Chamberlain AJ, Staples MP, McAvoy B. Nodular melanoma. No longer as simple as ABC. Aust Fam Physician 2003;32(9):706-9.
  7. Goodson AG, Grossman D. Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol 2009;60(5):719-35.
  8. Rueth NM, Xing Y, Chiang YJ, Cromwell KD, Ross MI, Lee JE, et al. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg 2014;259(6):1215-22.
  9. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206.
  10. Larsen IK, red. Cancer in Norway 2018: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2019. Tilgjengelig fra:
  11. Robsahm TE, Tretli S. Cutaneous malignant melanoma in Norway: variation by region of residence before and after the age 17. Cancer Causes Control 2001;12(6):569-76.
  12. de VE, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003;107(1):119-26.
  13. de VE, Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004;40(16):2355-66.
  14. MacKie RM, Bray CA, Hole DJ, Morris A, Nicolson M, Evans A, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002;360(9333):587-91.
  15. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49(6):1374-403.
  16. Globocan 2008: estimated cancer Incidence, Mortality, Prevalence and Disability-adjusted life years (DALYs) Worldwide in 2008 [nettside]. Lyon: IARC [oppdatert 2010; lest 1 nov. 2013]. Tilgjengelig fra:
  17. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, et al., red. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: Health NIo; 2006. NIH Publ No 05-5302. Tilgjengelig fra:
  18. Robsahm TE, Helsing P, Nilssen Y, Vos L, Rizvi SMH, Akslen LA, et al. High mortality due to cutaneous melanoma in Norway: a study of prognostic factors in a nationwide cancer registry. Clin Epidemiol 2018;10:537-48.
  19. Robsahm TE, Bergva G, Hestvik UE, Moller B. Sex differences in rising trends of cutaneous malignant melanoma in Norway, 1954-2008. Melanoma Res 2013;23(1):70-8.
  20. Scientific Committee on Health, Environmental and Emerging Risks - SCHEER. Opinion on biological effects of ultraviolet radiation relevant to health with particular reference to sunbeds for cosmetic purposes. Luxembourg: European Commission; 2016. Tilgjengelig fra:
  21. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005;41(1):45-60.
  22. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997;73(2):198-203.
  23. Gallagher RP, Spinelli JJ, Lee TK. Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005;14(3):562-6.
  24. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer 2007;120(5):1116-22.
  25. Ghiasvand R, Rueegg CS, Weiderpass E, Green AC, Lund E, Veierod MB. Indoor Tanning and Melanoma Risk: Long-Term Evidence From a Prospective Population-Based Cohort Study. Am J Epidemiol 2017;185(3):147-56.
  26. Kullavanijaya P, Lim HW. Photoprotection. J Am Acad Dermatol 2005;52(6):937-58.
  27. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011;29(3):257-63.
  28. Ghiasvand R, Weiderpass E, Green AC, Lund E, Veierod MB. Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study. J Clin Oncol 2016;34(33):3976-83.
  29. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009;27(32):5439-44.
  30. Robsahm TE, Tretli S, Torjesen PA, Babigumira R, Schwartz GG. Serum 25-hydroxyvitamin D levels predict cancer survival: a prospective cohort with measurements prior to and at the time of cancer diagnosis. Clin Epidemiol 2019;11:695-705.
  31. Gandini S, Raimondi S, Gnagnarella P, Dore JF, Maisonneuve P, Testori A. Vitamin D and skin cancer: a meta-analysis. Eur J Cancer 2009;45(4):634-41.
  32. Norval M, Wulf HC. Does chronic sunscreen use reduce vitamin D production to insufficient levels? Br J Dermatol 2009;161(4):732-6.
  33. Selvåg E. Legemidler og sol. Tidsskr Nor Laegeforen 2003;123(13-14):1860-1.
  34. Wu S, Han J, Feskanich D, Cho E, Stampfer MJ, Willett WC, et al. Citrus Consumption and Risk of Cutaneous Malignant Melanoma. J Clin Oncol 2015;33(23):2500-8.
  35. Katalinic A, Waldmann A, Weinstock MA, Geller AC, Eisemann N, Greinert R, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. Cancer 2012;118(21):5395-402.
  36. Stang A, Jöckel KH, Heidinger O. Skin cancer rates in North Rhine-Westphalia, Germany before and after the introduction of the nationwide skin cancer screening program (2000-2015). Eur J Epidemiol 2018;33(3):303-12.
  37. Kinsler VA, Birley J, Atherton DJ. Great Ormond Street Hospital for Children Registry for congenital melanocytic naevi: prospective study 1988-2007. Part 1-epidemiology, phenotype and outcomes. Br J Dermatol 2009;160(1):143-50.
  38. Foster RD, Williams ML, Barkovich AJ, Hoffman WY, Mathes SJ, Frieden IJ. Giant congenital melanocytic nevi: the significance of neurocutaneous melanosis in neurologically asymptomatic children. Plast Reconstr Surg 2001;107(4):933-41.
  39. Kinsler VA, Chong WK, Aylett SE, Atherton DJ. Complications of congenital melanocytic naevi in children: analysis of 16 years' experience and clinical practice. Br J Dermatol 2008;159(4):907-14.
  40. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005;41(1):28-44.
  41. Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women. III. Reproductive factors and oral contraceptive use. Am J Epidemiol 1995;141(10):943-50.
  42. Karagas MR, Stukel TA, Dykes J, Miglionico J, Greene MA, Carey M, et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 2002;86(7):1085-92.
  43. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002;3(3):159-65.
  44. Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008;159(3):669-76.
  45. Balch CM, Houghton AN, Sober AJ, Soong S-J, Atkins MB, Thompson JF, red. Cutaneous melanoma. 5 utg. Philadelphia: Lippingcott; 2009.
  46. Brierley JD, Gospodarowicz MK, Wittekind C, red. TNM classification of malignant tumours. 8. utg. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell; 2017.
  47. Edge SB, red. AJCC cancer staging manual/American Joint Committee on Cancer. New York: Springer; 2010.
  48. Clark WH, Jr., Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81(24):1893-904.
  49. Mihm MC, Jr., Mule JJ. Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response. Cancer Immunol Res 2015;3(8):827-35.
  50. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015;373(1):23-34.
  51. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2019;381(16):1535-46.
  52. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017;377(14):1345-56.
  53. Bostad L, red. Veileder i biopsibesvarelse av maligne svulster. Oslo: Den norske lægeforening; 2001.
  54. Chakera AH, Hesse B, Burak Z, Ballinger JR, Britten A, Caraco C, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging 2009;36(10):1713-42.
  55. Cook MG, Massi D, Szumera-Ciećkiewicz A, Van den Oord J, Blokx W, van Kempen LC, et al. An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma. Eur J Cancer 2019;114:1-7.
  56. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54(3):131-49; quiz 82-4.
  57. Morton R, Barbour A, Bell C, Mar V, Smithers M, Cancer Council Australia Melanoma Guidelines Working Party. What investigations should be performed following a diagnosis of primary cutaneous melanoma for asymptomatic stage I and stage II patients? I: Clinical practice guidelines for the diagnosis and management of melanoma [nettdokument]. Sydney: Cancer Council Australia [oppdatert 25. mai 2018; lest 17. mars 2020]. Tilgjengelig fra:
  58. Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, et al. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019;17(4):367-402.
  59. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 2011;103(2):129-42.
  60. Bochev P, Klisarova A, Kaprelyan A, Chaushev B, Dancheva Z. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors. Hell J Nucl Med 2012;15(2):125-9.
  61. Chai CY, Zager JS, Szabunio MM, Marzban SS, Chau A, Rossi RM, et al. Preoperative ultrasound is not useful for identifying nodal metastasis in melanoma patients undergoing sentinel node biopsy: preoperative ultrasound in clinically node-negative melanoma. Ann Surg Oncol 2012;19(4):1100-6.
  62. Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol 2014;23(1):11-6.
  63. Goyal S, Silk AW, Tian S, Mehnert J, Danish S, Ranjan S, et al. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. JAMA Oncol 2015;1(5):668-76.
  64. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 2010;28(18):3042-7.
  65. Schroer-Gunther MA, Wolff RF, Westwood ME, Scheibler FJ, Schurmann C, Baumert BG, et al. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Syst Rev 2012;1:62.
  66. Nasjonalt kvalitetsregister for melanom. Årsrapport 2018: resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for melanom. Oslo: Kreftregisteret; 2019. Tilgjengelig fra:
  67. Gershenwald JE, Scolyer RA. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol 2018;25(8):2105-10.
  68. Holtkamp LHJ, Read RL, Emmett L, Thompson JF, Nieweg OE. Futility of imaging to stage melanoma patients with a positive sentinel lymph node. Melanoma Res 2017;27(5):457-62.
  69. Gold JS, Jaques DP, Busam KJ, Brady MS, Coit DG. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 2007;14(7):2133-40.
  70. Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther 2018;18(8):775-84.
  71. Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009;27(28):4774-80.
  72. Schule SC, Eigentler TK, Garbe C, la Fougere C, Nikolaou K, Pfannenberg C. Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. Eur J Nucl Med Mol Imaging 2016;43(3):482-8.
  73. Millward M, Menzies A, Atkinson V, Brown M, Haydon A, Cancer Council Australia Melanoma Guidelines Working Party. What investigations should be performed when Stage IV melanoma is diagnosed? I: Clinical practice guidelines for the diagnosis and management of melanoma [nettdokument]. Sydney: Cancer Council Australia [oppdatert 25. mai 2018; lest 17. mars 2020]. Tilgjengelig fra:
  74. Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. Bmj 2012;344:e2718.
  75. Sainsbury R, Haward B, Rider L, Johnston C, Round C. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet 1995;345(8960):1265-70.
  76. Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum Genet 2009;126(4):499-510.
  77. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de PB, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94(12):894-903.
  78. Hansson J, Bergenmar M, Hofer PA, Lundell G, Mansson-Brahme E, Ringborg U, et al. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program. J Clin Oncol 2007;25(19):2819-24.
  79. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000;92(12):1006-10.
  80. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009;41(8):920-5.
  81. Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, et al. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 2008;47(2):175-84.
  82. Molven A, Grimstvedt MB, Steine SJ, Harland M, Avril MF, Hayward NK, et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer 2005;44(1):10-8.
  83. Lynch HT, Fusaro RM, Lynch JF, Brand R. Pancreatic cancer and the FAMMM syndrome. Fam Cancer 2008;7(1):103-12.
  84. Landi S. Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. Mutat Res 2009;681(2-3):299-307.
  85. Hunger RE, Seyed Jafari SM, Angermeier S, Shafighi M. Excision of fascia in melanoma thicker than 2 mm: no evidence for improved clinical outcome. Br J Dermatol 2014;171(6):1391-6.
  86. Lens MB, Nathan P, Bataille V. Excision margins for primary cutaneous melanoma: updated pooled analysis of randomized controlled trials. Arch Surg 2007;142(9):885-91.
  87. Gillgren P, Drzewiecki KT, Niin M, Gullestad HP, Hellborg H, Månsson-Brahme E, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 2011;378(9803):1635-42.
  88. Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev 2009;(4):CD004835.
  89. Wheatley K, Wilson J, Gaunt P, Marsden J. Are narrow surgical excision margins for primary cutaneous melanoma safe? An updated systematic review and meta-analysis. J Dtsch Dermatol Ges 2013;7):10.
  90. Sladden M, Nieweg OE, Hovwle J, Coverntry B, Cancer Council Australia Melanoma Guidelines Working Party. What are the recommended safety margins for radical excision of primary melanoma? I: Clinical practice guidelines for the diagnosis and management of melanoma [nettdokument]. Sydney: Cancer Council Australia [oppdatert 17. mai 2018; lest 18. mai 2018]. Tilgjengelig fra:
  91. Hayes AJ, Maynard L, Coombes G, Newton-Bishop J, Timmons M, Cook M, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol 2016;17(2):184-92.
  92. Haydu LE, Stollman JT, Scolyer RA, Spillane AJ, Quinn MJ, Saw RP, et al. Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1-2 mm in Thickness): Analysis of 2131 Patients Treated at a Single Center. Ann Surg Oncol 2016;23(4):1071-81.
  93. Tzellos T, Kyrgidis A, Mocellin S, Chan AW, Pilati P, Apalla Z. Interventions for melanoma in situ, including lentigo maligna. Cochrane Database Syst Rev 2014;(12):Cd010308.
  94. Hudson LE, Maithel SK, Carlson GW, Rizzo M, Murray DR, Hestley AC, et al. 1 or 2 cm margins of excision for T2 melanomas: do they impact recurrence or survival? Ann Surg Oncol 2013;20(1):346-51.
  95. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. Eur J Cancer 2012;48(15):2375-90.
  96. Mocellin S, Pasquali S, Nitti D. The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins. Ann Surg 2011;253(2):238-43.
  97. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003;46(6):419-26.
  98. Lens MB, Dawes M, Goodacre T, Bishop JA. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Arch Surg 2002;137(10):1101-5.
  99. Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001;8(2):101-8.
  100. Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson H, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000;89(7):1495-501.
  101. Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998;14(4):272-5.
  102. MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelmarT) [pågående studie]. 2015-2026. NCT02385214. Tilgjengelig fra:
  103. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127(4):392-9.
  104. de Wilt JH, van Akkooi AC, Verhoef C, Eggermont AM. Detection of melanoma micrometastases in sentinel nodes - the cons. Surg Oncol 2008;17(3):175-81.
  105. Danmark: Modermærkekræft. København: Sundhedsstyrelsen; 2008.
  106. Populärvetenskapliga fakta om cancer: cancer i siffror 2009. Stockholm: Sosialstyrelsen i Sverige; 2009. Tilgjengelig fra:
  107. New German Guidelines for Malignant Melanoma. 2011.
  108. New ASCO, SSO guidelines for sentinel lymph node biopsy in melanoma. Oncology (WillistonPark) 2012;26(9):841-2.
  109. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 2012;30(23):2912-8.
  110. Guggenheim MM, Hug U, Jung FJ, Rousson V, Aust MC, Calcagni M, et al. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma. Ann Surg 2008;247(4):687-93.
  111. Kretschmer L, Thoms KM, Peeters S, Haenssle H, Bertsch HP, Emmert S. Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res 2008;18(1):16-21.
  112. Amin MB, Edge S, Greene FL, Byrd DR, Brookland RK, Washington MK, et al., red. AJCC Cancer Staging Manual. 8. utg. New York: Springer-Verlag; 2017.
  113. Egger ME, Stevenson M, Bhutiani N, Jordan AC, Scoggins CR, Philips P, et al. Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8(th) Edition American Joint Committee on Cancer Staging System? J Am Coll Surg 2019;228(4):466-72.
  114. Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, et al. Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. J Clin Oncol 2020;38(14):1591-601.
  115. Agnese DM, Abdessalam SF, Burak WE, Jr., Magro CM, Pozderac RV, Walker MJ. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003;134(4):542-7.
  116. Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw 2009;7(3):308-17.
  117. Warycha MA, Zakrzewski J, Ni Q, Shapiro RL, Berman RS, Pavlick AC, et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm). Cancer 2009;115(4):869-79.
  118. Amersi F, Morton DL. The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg 2007;41:241-56.
  119. Caraco C, Celentano E, Lastoria S, Botti G, Ascierto PA, Mozzillo N. Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters. Ann Surg Oncol 2004;11(3 Suppl):198S-202S.
  120. Gyorki DE, Sanelli A, Herschtal A, Lazarakis S, McArthur GA, Speakman D, et al. Sentinel Lymph Node Biopsy in T4 Melanoma: An Important Risk-Stratification Tool. Ann Surg Oncol 2016;23(2):579-84.
  121. Karakousis GC, Pandit-Taskar N, Hsu M, Panageas K, Atherton S, Ariyan C, et al. Prognostic significance of drainage to pelvic nodes at sentinel lymph node mapping in patients with extremity melanoma. Melanoma Res 2013;23(1):40-6.
  122. Rossi CR, Mocellin S, Scagnet B, Foletto M, Vecchiato A, Pilati P, et al. The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol 2003;83(2):80-4.
  123. Ulrich J, van Akkooi AJ, Eggermont AM, Voit C. New developments in melanoma: utility of ultrasound imaging (initial staging, follow-up and pre-SLNB). Expert Rev Anticancer Ther 2011;11(11):1693-701.
  124. Voit C, Kron M, Schafer G, Schoengen A, Audring H, Lukowsky A, et al. Ultrasound-guided fine needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol 2006;13(12):1682-9.
  125. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 2017;376(23):2211-22.
  126. Liu LC, Parrett BM, Jenkins T, Lee W, Morita E, Treseler P, et al. Selective sentinel lymph node dissection for melanoma: importance of harvesting nodes with lower radioactive counts without the need for blue dye. Ann Surg Oncol 2011;18(10):2919-24.
  127. McMasters KM, Reintgen DS, Ross MI, Wong SL, Gershenwald JE, Krag DN, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol 2001;8(3):192-7.
  128. Yao K, Balch G, Winchester DJ. Multidisciplinary treatment of primary melanoma. Surg Clin North Am 2009;89(1):267-81, xi.
  129. Thomas JM. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 2008;5(1):18-23.
  130. Kyrgidis A, Tzellos T, Mocellin S, Apalla Z, Lallas A, Pilati P, et al. Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma. Cochrane Database Syst Rev 2015;(5):CD010307.
  131. Morton DL. Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis 2012;29(7):699-706.
  132. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 2016;17(6):757-67.
  133. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 2018;378(19):1789-801.
  134. Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017;377(19):1813-23.
  135. van Akkooi AC, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 2006;17(10):1578-85.
  136. Scolyer RA, Murali R, McCarthy SW, Thompson JF. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol 2008;25(2):100-11.
  137. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355(13):1307-17.
  138. Pasquali S, Mocellin S, Campana LG, Bonandini E, Montesco MC, Tregnaghi A, et al. Early (sentinel lymph node biopsy-guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases : personal experience and literature meta-analysis. Cancer 2010;116(5):1201-9.
  139. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014;370(7):599-609.
  140. Faries MB, Thompson JF, Cochran A, Elashoff R, Glass EC, Mozzillo N, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010;17(12):3324-9.
  141. Thompson JF, Kam PC. Current status of isolated limb infusion with mild hyperthermia for melanoma. Int J Hyperthermia 2008;24(3):219-25.
  142. Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros W, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008;15(8):2195-205.
  143. Hill S, Thomas JM. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996;83(4):509-12.
  144. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, et al. Electrochemotherapy - An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 2006;4(11):3-13.
  145. Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur J Cancer Suppl 2006;4(11):14-25.
  146. Hughes TM, A'Hern RP, Thomas JM. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br J Surg 2000;87(7):892-901.
  147. Balch CM, Ross MI. Melanoma patients with iliac nodal metastases can be cured. Ann Surg Oncol 1999;6(3):230-1.
  148. Haagensen CD. Diseases of the breast. Philadelphia: Saunders; 1971.
  149. Stone CA, Goodacre TE. Surgical management of regional lymph nodes in primary cutaneous malignant melanoma. Br J Surg 1995;82(8):1015-22.
  150. Karakousis CP, Emrich LJ, Rao U. Groin dissection in malignant melanoma. Am J Surg 1986;152(5):491-5.
  151. Sterne GD, Murray DS, Grimley RP. Ilioinguinal block dissection for malignant melanoma. Br J Surg 1995;82(8):1057-9.
  152. Benlyazid A, Thariat J, Temam S, Malard O, Florescu C, Choussy O, et al. Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study. Arch Otolaryngol Head Neck Surg 2010;136(12):1219-25.
  153. Mendenhall WM, Amdur RJ, Grobmyer SR, George TJ, Jr., Werning JW, Hochwald SN, et al. Adjuvant radiotherapy for cutaneous melanoma. Cancer 2008;112(6):1189-96.
  154. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012;13(6):589-97.
  155. Nasjonalt kvalitetsregister for melanom. Figur 3.24 og 3.25. I: Årsrapport 2018 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for melanom. Oslo: Kreftregisteret; 2019. Tilgjengelig fra:
  156. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10(5):1670-7.
  157. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010;102(7):493-501.
  158. Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009;27(18):2916-23.
  159. Hansson J, Aamdal S, Brandberg Y, Bastholt L, Hernberg M, Nilsson B, et al. Health-related quality of life (HRQOL) in the Nordic randomized trial of adjuvant intermediate-dose interferon alfa-2b in high-risk melanoma [2011 Asco Annual Meeting]. J Clin Oncol 2011;29(suppl):abstr. 8547.
  160. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 2016;375(19):1845-55.
  161. Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, et al. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol 2018:JCO1801219 [Epub ahead of print].
  162. Dummer R, Schadendorf D, Hauschild A, Santinami M, Atkinson VG, Mandala M, et al. 1250PEstimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. Ann Oncol 2018;29(suppl_8):mdy289.006.
  163. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017;377(19):1824-35.
  164. Larsen IK, red. Cancer in Norway 2013: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2015. Tilgjengelig fra:
  165. Dummer R, Guggenheim M, Arnold AW, Braun R, von Moos R. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2011;141:w13320.
  166. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 2007;17(6):393-9.
  167. Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M. A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol 2013;6(9):18-26.
  168. DMG Guidelines 2013. Herlev: Dansk Melanom Gruppe; 2013. Tilgjengelig fra:
  169. Cancer Practice Guidelines for the Management of Melanoma in Australia and New Zealand: Evidence-based Best Practice Guidelines. Wellington: Cancer Council Australia/Australian Cancer Network/Ministry of Health, New Zealand; 2008. Tilgjengelig fra:
  170. NCCN Clinical Practice Guidelines in Oncology: Melanoma. Fort Washington, PA: National Comprehensive Cancer Network; 2013.
  171. Melanoma: assessment and management. Cardiff: National Collaborating Centre for Cancer; 2015. NICE guideline NG14. Tilgjengelig fra:
  172. Livingstone E, Krajewski C, Eigentler TK, Windemuth-Kieselbach C, Benson S, Elsenbruch S, et al. Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study. Eur J Cancer 2015;51(5):653-67.
  173. Rueth NM, Cromwell KD, Cormier JN. Long-term follow-up for melanoma patients: is there any evidence of a benefit? Surg Oncol Clin N Am 2015;24(2):359-77.
  174. Rutkowski P, Lugowska I. Follow-up in melanoma patients. Memo 2014;7(2):83-6.
  175. Balch CM, Houghton AN, Milton GW, red. Cutaneous Melanoma. 2 utg. Philadelphia: Lippincott; 1992. s 165-99
  176. Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson J. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. Clin Epidemiol 2016;8:109-22.
  177. Kreftregisteret. Personlig meddelse. 2015.
  178. Voit C, van Akkooi AC, Schafer-Hesterberg G, Schoengen A, Kowalczyk K, Roewert JC, et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. J Clin Oncol 2010;28(5):847-52.
  179. Dessinioti C, Dimou N, Geller AC, Stergiopoulou A, Lo S, Keim U, et al. Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. J Natl Cancer Inst 2019;111(12):1314-22.
  180. Lattanzi M, Lee Y, Simpson D, Moran U, Darvishian F, Kim RH, et al. Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. J Natl Cancer Inst 2019;111(2):180-8.
  181. Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol 2009;145(4):427-34.
  182. Chopra A, Sharma R, Rao UNM. Pathology of Melanoma. Surg Clin North Am 2020;100(1):43-59.
  183. Bello DM, Chou JF, Panageas KS, Brady MS, Coit DG, Carvajal RD, et al. Prognosis of acral melanoma: a series of 281 patients. Ann Surg Oncol 2013;20(11):3618-25.
  184. Seneffekter etter kreftbehandling: faglige råd. Oslo: Helsedirektoratet; 2017. IS-2551. Tilgjengelig fra:
  185. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322(8):494-500.
  186. Miller JD. Surgical excision for single cerebral metastasis? Lancet 1993;341(8860):1566.
  187. Overett TK, Shiu MH. Surgical treatment of distant metastatic melanoma. Indications and results. Cancer 1985;56(5):1222-30.
  188. Meyer T, Merkel S, Goehl J, Hohenberger W. Surgical therapy for distant metastases of malignant melanoma. Cancer 2000;89(9):1983-91.
  189. Jimenez-Requena F, Delgado-Bolton RC, Fernandez-Perez C, Gambhir SS, Schwimmer J, Perez-Vazquez JM, et al. Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging 2010;37(2):284-300.
  190. Fenig E, Eidelevich E, Njuguna E, Katz A, Gutman H, Sulkes A, et al. Role of radiation therapy in the management of cutaneous malignant melanoma. Am J Clin Oncol 1999;22(2):184-6.
  191. Peters JL, Byers RM, Ang KK. Radiotherapy for melanoma. I: Balch CM, Hougton AN, Milton GW, Sober AJ, Soong S, red. Cutaneous melanoma. 2 utg. Philadelphia: Lippincott; 1992. s. 165-99.
  192. Waldeland E, Brustugun OT, Ramberg C, Helland Å. Stereotaktisk bestråling av columnametastaser. Tidsskr Nor Legeforen 2012;132(22):2478-9.
  193. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010;77(3):655-61.
  194. Noel G, Simon JM, Valery CA, Cornu P, Boisserie G, Ledu D, et al. Linac radiosurgery for brain metastasis of melanoma. Stereotact Funct Neurosurg 2002;79(3-4):245-55.
  195. Hong AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, Lo SN, Haydu LE, et al. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. J Clin Oncol 2019;37(33):3132-41.
  196. Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018;19(5):672-81.
  197. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13(11):1087-95.
  198. Hong AM, Suo C, Valenzuela M, Haydu LE, Jacobsen KD, Reisse CH, et al. Low incidence of melanoma brain metastasis in the hippocampus. Radiother Oncol 2014;111(1):59-62.
  199. Brennum J, Kosteljanetz M, Roed HM. Hjernemetastaser. Ugeskr Læger 2002;164(27):3522-6.
  200. Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, et al. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunol Res 2015;3(6):610-9.
  201. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23.
  202. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010;21(8):1712-7.
  203. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11(2):155-64.
  204. Robert C, Thomas L, Bondarenko I, O'Day S, JW MD, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517-26.
  205. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012;18(12):3242-9.
  206. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16.
  207. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380(9839):358-65.
  208. Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012;6:391-405.
  209. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363(9):809-19.
  210. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 2013;49(6):1297-304.
  211. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):320-30.
  212. Ascierto PA, McArthur GA, Dreno B, Larkin J, Liszkay G, Maio M, et al. coBRIM: A phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation-positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519). J Transl Med 2014;13(Suppl 1):O4.
  213. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018;19(10):1315-27.
  214. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16(4):375-84.
  215. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015;372(26):2521-32.
  216. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16(8):908-18.
  217. Daud A. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 2015;33(Suppl):abstr 9005.
  218. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009;9(5):587-95.
  219. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40(12):1825-36.
  220. Kroon HM, Thompson JF. Isolated limb infusion: a review. J Surg Oncol 2009;100(2):169-77.
  221. Grunhagen DJ, van EB, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 2005;12(8):609-15.
  222. Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BB. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur J Surg Oncol 2006;32(3):318-24.
  223. Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen. rev. utg. Oslo: Helsedirektoratet; 2019. IS-2800. Tilgjengelig fra:
  224. Lucke A. Die Lehre von den Geschwulsten in anatomishcer und klinischer Beziehung. I: Handbuch der allgemeinen und speciellen Chirurgie. Enke: Erlangen; 1869. s. 244.
  225. Kreftregisteret. Personlig meddelelse 2008.
  226. Patel SG, Prasad ML, Escrig M, Singh B, Shaha AR, Kraus DH, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002;24(3):247-57.
  227. Oral malignant melanoma [nettside]. [oppdatert 7. sept. 2010; lest Sept. 2011]. Tilgjengelig fra:
  228. Stang A, Streller B, Eisinger B, Jöckel KH. Population-based incidence rates of malignant melanoma of the vulva in Germany. Gynecol Oncol 2005;96(1):216-21.
  229. Verschraegen CF, Benjapibal M, Supakarapongkul W, Levy LB, Ross M, Atkinson EN, et al. Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. Int J Gynecol Cancer 2001;11(5):359-64.
  230. Frumovitz M, Etchepareborda M, Sun CC, Soliman PT, Eifel PJ, Levenback CF, et al. Primary malignant melanoma of the vagina. Obstet Gynecol 2010;116(6):1358-65.
  231. Irvin WP, Jr., Legallo RL, Stoler MH, Rice LW, Taylor PT, Jr., Andersen WA. Vulvar melanoma: a retrospective analysis and literature review. Gynecol Oncol 2001;83(3):457-65.
  232. Lotem M, Anteby S, Peretz T, Ingber A, Avinoach I, Prus D. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecol Oncol 2003;88(1):45-50.
  233. DeMatos P, Tyler D, Seigler HF. Mucosal melanoma of the female genitalia: a clinicopathologic study of forty-three cases at Duke University Medical Center. Surgery 1998;124(1):38-48.
  234. Suwandinata FS, Bohle RM, Omwandho CA, Tinneberg HR, Gruessner SE. Management of vulvar melanoma and review of the literature. Eur J Gynaecol Oncol 2007;28(3):220-4.
  235. Dhar KK, Das N, Brinkman DA, Beynon JL, Woolas RP. Utility of sentinel node biopsy in vulvar and vaginal melanoma: report of two cases and review of the literature. Int J Gynecol Cancer 2007;17(3):720-3.
  236. Trimble EL, Lewis JL, Jr., Williams LL, Curtin JP, Chapman D, Woodruff JM, et al. Management of vulvar melanoma. Gynecol Oncol 1992;45(3):254-8.
  237. Jaramillo BA, Ganjei P, Averette HE, Sevin BU, Lovecchio JL. Malignant melanoma of the vulva. Obstet Gynecol 1985;66(3):398-401.
  238. Voit CA, van Akkooi AC, Schäfer-Hesterberg G, Schoengen A, Schmitz PI, Sterry W, et al. Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol 2009;27(30):4994-5000.
  239. Tchelebi L, Guirguis A, Ashamalla H. Rectal melanoma: epidemiology, prognosis, and role of adjuvant radiation therapy. J Cancer Res Clin Oncol 2016;142(12):2569-75.
  240. Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007;14(6):1924-33.
  241. Koskivuo I, Kemppainen J, Giordano S, Seppänen M, Veräjänkorva E, Vihinen P, et al. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma(). Acta Oncol 2016;55(11):1355-9.
  242. Vensby PH, Schmidt G, Kjær A, Fischer BM. The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis. Am J Nucl Med Mol Imaging 2017;7(6):255-62.
  243. van Geel AN, den Bakker MA, Kirkels W, Horenblas S, Kroon BB, de Wilt JH, et al. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature. Urology 2007;70(1):143-7.
  244. Malik A, Hull TL, Floruta C. What is the best surgical treatment for anorectal melanoma? Int J Colorectal Dis 2004;19(2):121-3.
  245. Bullard KM, Tuttle TM, Rothenberger DA, Madoff RD, Baxter NN, Finne CO, et al. Surgical therapy for anorectal melanoma. J Am Coll Surg 2003;196(2):206-11.
  246. Pessaux P, Pocard M, Elias D, Duvillard P, Avril MF, Zimmerman P, et al. Surgical management of primary anorectal melanoma. Br J Surg 2004;91(9):1183-7.
  247. Yeh JJ, Shia J, Hwu WJ, Busam KJ, Paty PB, Guillem JG, et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg 2006;244(6):1012-7.
  248. Ross M, Pezzi C, Pezzi T, Meurer D, Hickey R, Balch C. Patterns of failure in anorectal melanoma. A guide to surgical therapy. Arch Surg 1990;125(3):313-6.
  249. Konstadoulakis MM, Ricaniadis N, Walsh D, Karakousis CP. Malignant melanoma of the anorectal region. J Surg Oncol 1995;58(2):118-20.
  250. Thibault C, Sagar P, Nivatvongs S, Ilstrup DM, Wolff BG. Anorectal melanoma--an incurable disease? Dis Colon Rectum 1997;40(6):661-8.
  251. Weyandt GH, Eggert AO, Houf M, Raulf F, Bröcker EB, Becker JC. Anorectal melanoma: surgical management guidelines according to tumour thickness. Br J Cancer 2003;89(11):2019-22.
  252. Slingluff CL, Jr., Vollmer RT, Seigler HF. Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients. Surgery 1990;107(1):1-9.
  253. Roumen RM. Anorectal melanoma in The Netherlands: a report of 63 patients. Eur J Surg Oncol 1996;22(6):598-601.
  254. Moozar KL, Wong CS, Couture J. Anorectal malignant melanoma: treatment with surgery or radiation therapy, or both. Can J Surg 2003;46(5):345-9.
  255. Goldman S, Glimelius B, Påhlman L. Anorectal malignant melanoma in Sweden. Report of 49 patients. Dis Colon Rectum 1990;33(10):874-7.
  256. Antoniuk PM, Tjandra JJ, Webb BW, Petras RE, Milsom JW, Fazio VW. Anorectal malignant melanoma has a poor prognosis. Int J Colorectal Dis 1993;8(2):81-6.
  257. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001;119(7):969-82.
  258. Jensen OA. Malignant melanomas of the uvea in Denmark 1943-1952: a clinical, histopathological, and prognostic study. Acta Ophthalmol 1963;43(Suppl 75):1-220.
  259. Raivio I. Uveal melanoma in Finland. An epidemiological, clinical, histological and prognostic study. Acta Ophthalmol Suppl 1977;(133):1-64.
  260. Bergman L, Seregard S, Nilsson B, Ringborg U, Lundell G, Ragnarsson-Olding B. Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci 2002;43(8):2579-83.
  261. Osterlind A. Trends in incidence of ocular malignant melanoma in Denmark 1943-1982. Int J Cancer 1987;40(2):161-4.
  262. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003;110(5):962-5.
  263. Isager P, Osterlind A, Engholm G, Heegaard S, Lindegaard J, Overgaard J, et al. Uveal and conjunctival malignant melanoma in Denmark, 1943-97: incidence and validation study. Ophthalmic Epidemiol 2005;12(4):223-32.
  264. Seregard S. Conjunctival melanoma. Surv Ophthalmol 1998;42(4):321-50.
  265. Singh AD, Shields CL, Shields JA, Sato T. Uveal melanoma in young patients. Arch Ophthalmol 2000;118(7):918-23.
  266. Guenel P, Laforest L, Cyr D, Fevotte J, Sabroe S, Dufour C, et al. Occupational risk factors, ultraviolet radiation, and ocular melanoma: a case-control study in France. Cancer Causes Control 2001;12(5):451-9.
  267. Shah CP, Weis E, Lajous M, Shields JA, Shields CL. Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis. Ophthalmology 2005;112(9):1599-607.
  268. Stang A, Anastassiou G, Ahrens W, Bromen K, Bornfeld N, Jockel KH. The possible role of radiofrequency radiation in the development of uveal melanoma. Epidemiology 2001;12(1):7-12.
  269. Johansen C, Boice JD, Jr., McLaughlin JK, Christensen HC, Olsen JH. Mobile phones and malignant melanoma of the eye. Br J Cancer 2002;86(3):348-9.
  270. Sumich P, Mitchell P, Wang JJ. Choroidal nevi in a white population: the Blue Mountains Eye Study. Arch Ophthalmol 1998;116(5):645-50.
  271. Ng CH, Wang JJ, Mitchell P, Amirul Islam FM, Wong TY. Prevalence and characteristics of choroidal nevi in an Asian vs white population. Arch Ophthalmol 2009;127(3):314-9.
  272. Ganley JP, Comstock GW. Benign nevi and malignant melanomas of the choroid. Am J Ophthalmol 1973;76(1):19-25.
  273. Butler P, Char DH, Zarbin M, Kroll S. Natural history of indeterminate pigmented choroidal tumors. Ophthalmology 1994;101(4):710-6.
  274. Shields CL, Cater J, Shields JA, Singh AD, Santos MC, Carvalho C. Combination of clinical factors predictive of growth of small choroidal melanocytic tumors. Arch Ophthalmol 2000;118(3):360-4.
  275. Shields CL, Furuta M, Berman EL, Zahler JD, Hoberman DM, Dinh DH, et al. Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol 2009;127(8):981-7.
  276. Eskelin S, Kivela T. Mode of presentation and time to treatment of uveal melanoma in Finland. Br J Ophthalmol 2002;86(3):333-8.
  277. Boldt HC, Byrne SF, Gilson MM, Finger PT, Green RL, Straatsma BR, et al. Baseline echographic characteristics of tumors in eyes of patients enrolled in the Collaborative Ocular Melanoma Study: COMS report no. 29. Ophthalmology 2008;115(8):1390-7.
  278. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1. Arch Ophthalmol 1990;108(9):1268-73.
  279. Char DH, Miller T. Accuracy of presumed uveal melanoma diagnosis before alternative therapy. Br J Ophthalmol 1995;79(7):692-6.
  280. Eide N, Walaas L. Fine-needle aspiration biopsy and other biopsies in suspected intraocular malignant disease: a review. Acta Ophthalmol 2009;87(6):588-601.
  281. Eskelin S, Pyrhonen S, Hahka-Kemppinen M, Tuomaala S, Kivela T. A prognostic model and staging for metastatic uveal melanoma. Cancer 2003;97(2):465-75.
  282. Eskelin S, Pyrhonen S, Summanen P, Prause JU, Kivela T. Screening for metastatic malignant melanoma of the uvea revisited. Cancer 1999;85(5):1151-9.
  283. Wagoner MD, Albert DM. The incidence of metastases from untreated ciliary body and choroidal melanoma. Arch Ophthalmol 1982;100(6):939-40.
  284. Finger PT, Kurli M, Reddy S, Tena LB, Pavlick AC. Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 2005;89(10):1270-4.
  285. Malignant melanoma of the uvea (B). I: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, red. AJCC cancer staging manual. New York: Springer; 2009. s. 547-60.
  286. Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol Scand 1995;73(4):340-4.
  287. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res 2001;11(3):255-63.
  288. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006;124(12):1684-93.
  289. Mortality in patients with small choroidal melanoma. COMS report no. 4. The Collaborative Ocular Melanoma Study Group. Arch Ophthalmol 1997;115(7):886-93.
  290. Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology 2001;108(2):348-66.
  291. Mudhar HS, Parsons MA, Sisley K, Rundle P, Singh A, Rennie IG. A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathology 2004;45(1):1-12.
  292. McLean IW, Ainbinder DJ, Gamel JW, McCurdy JB. Choroidal-ciliary body melanoma. A multivariate survival analysis of tumor location. Ophthalmology 1995;102(7):1060-4.
  293. Folberg R, Rummelt V, Parys-Van GR, Hwang T, Woolson RF, Pe'er J, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993;100(9):1389-98.
  294. Robertson DM. Cytogenetics in the management of uveal melanoma: are we there yet? Arch Ophthalmol 2008;126(3):409-10.
  295. Young TA, Burgess BL, Rao NP, Gorin MB, Straatsma BR. High-density genome array is superior to fluorescence in-situ hybridization analysis of monosomy 3 in choroidal melanoma fine needle aspiration biopsy. Mol Vis 2007;13:2328-33.
  296. Shields CL, Ganguly A, Materin MA, Teixeira L, Mashayekhi A, Swanson LA, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: the Deborah Iverson, MD, Lectureship. Arch Ophthalmol 2007;125(8):1017-24.
  297. Sisley K, Nichols C, Parsons MA, Farr R, Rees RC, Rennie IG. Clinical applications of chromosome analysis, from fine needle aspiration biopsies, of posterior uveal melanomas. Eye (Lond) 1998;12 ( Pt 2):203-7.
  298. Damato EM, Damato B, Sibbring JS, Coupland SE. Ciliary body melanoma with partial deletion of chromosome 3 detected with multiplex ligation-dependent probe amplification. Graefes Arch Clin Exp Ophthalmol 2008;246(11):1637-40.
  299. Naus NC, Verhoeven AC, van DE, Slater R, Mooy CM, Paridaens DA, et al. Detection of genetic prognostic markers in uveal melanoma biopsies using fluorescence in situ hybridization. Clin Cancer Res 2002;8(2):534-9.
  300. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996;347(9010):1222-5.
  301. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64(20):7205-9.
  302. Shields CL, Materin MA, Teixeira L, Mashayekhi A, Ganguly A, Shields JA. Small choroidal melanoma with chromosome 3 monosomy on fine-needle aspiration biopsy. Ophthalmology 2007;114(10):1919-24.
  303. Seregard S. Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1,066 patients. Acta Ophthalmol Scand 1999;77(4):414-7.
  304. Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 2000;118(9):1219-28.
  305. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 2002;120(12):1665-71.
  306. Desjardins L, Lumbroso-Le RL, Levy-Gabriel C, Dendale R, Delacroix S, Nauraye C, et al. Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. Ophthalmic Res 2006;38(5):255-60.
  307. Aaberg TM, Jr., Bergstrom CS, Hickner ZJ, Lynn MJ. Long-term results of primary transpupillary thermal therapy for the treatment of choroidal malignant melanoma. Br J Ophthalmol 2008;92(6):741-6.
  308. Shields CL, Shields JA, Perez N, Singh AD, Cater J. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology 2002;109(2):225-34.
  309. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44(11):4651-9.
  310. Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 1999;106(8):1571-7.
  311. Shields CL, Shields JA, Karlsson U, Menduke H, Brady LW. Enucleation after plaque radiotherapy for posterior uveal melanoma. Histopathologic findings. Ophthalmology 1990;97(12):1665-70.
  312. Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002;109(12):2197-206.
  313. Pach JM, Robertson DM. Metastasis from untreated uveal melanomas. Arch Ophthalmol 1986;104(11):1624-5.
  314. Kivela T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin 2006;46(1):133-49.
  315. Singh AD, Borden EC. Metastatic uveal melanoma. Ophthalmol Clin North Am 2005;18(1):143-50, ix.
  316. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001;119(5):670-6.
  317. Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol 2009;35(11):1192-7.
  318. Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 2009;93(8):1042-6.
  319. Alexander HR, Jr., Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003;9(17):6343-9.
  320. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006;17(4):578-83.
  321. Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, Leyvraz S, et al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 1998;24(2):127-30.
  322. Kodjikian L, Grange JD, Rivoire M. Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy. Graefes Arch Clin Exp Ophthalmol 2005;243(6):622-4.
  323. Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol 2010;33(5):474-80.
  324. Kennedy AS, Nutting C, Jakobs T, Cianni R, Notarianni E, Ofer A, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009;27(6):682-90.
  325. Nasjonal strategi for kreftområdet 2006-2009. Oslo: Helse- og omsorgsdepartementet; 2006. Tilgjengelig fra:
  326. Sammen - mot kreft: nasjonal kreftstrategi 2013–2017. Oslo: Helse- og omsrogsdepartementet; 2013. Tilgjengelig fra:
  327. Leve med kreft: Nasjonal kreftstrategi (2018–2022). Oslo: Helse- og omsrogsdepartementet; 2018. Tilgjengelig fra: